We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sigma-Aldrich Signs Exclusive Agreement with Rubicon Genomics to Commercialize Transplex™

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Sigma-Aldrich has announced an exclusive licensing agreement with Rubicon Genomics to further develop and commercialize their TransPlex™ Whole Transcriptome Amplification (WTA) technology.

The TransPlex technology is a method which can be used for amplifying total RNA from a variety of sample sources such as animals, plants, and micro-organisms.

Under the terms of the agreement, Rubicon retains all rights to TransPlex™ for molecular diagnostics.

"We are excited to have this opportunity to expand our relationship with Rubicon," said Keith Jolliff, Director of Marketing for Genomics and Functional Genomics.

"Sigma-Aldrich is committed to bringing best-in-class- technologies to the genomic research community, and the TransPlex™ Whole Transcriptome Amplification kit is clearly in that category."

John Langmore, VP of Commercial Development at Rubicon, said: "Rubicon is very pleased that Sigma-Aldrich will be marketing TransPlex kits to complement the very successful GenomePlex® Whole Genome Amplification kits. We have confidence that their customers will embrace TransPlex for biological research and development of diagnostic products."

TransPlex WTA is designed to create a cDNA library from the isolated RNA template and to amplify the library in a single PCR reaction as the TransPlex reagents and protocols are optimized to ensure a linear representation of all expressed genes and exons that allow RNA samples to be amplified 1,000-10,000 fold in less than four hours.

This technology is made to work well even when the RNA is partially degraded, as in formalin-fixed paraffin-embedded tissue.